R-PMDT: Rituximab (375 mg/m², IV infusion) is given on day 0; methotrexate (3.5 g/m², IV infusion over 3 hours) on day 1; dexamethasone (20 mg, IV infusion) on days 1-4; thiotepa (30 mg/m², IV infusion) on day 1; and pirtobrutinib (200 mg, oral) on days 4-21 or until the day prior to methotrexate administration in the next cycle.
Study summary
A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The primary objective is to assess the overall response rate (ORR) of R-PMDT. Secondary objectives include evaluating the complete response rate, progression-free survival (PFS), overall survival (OS), and safety.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Newly diagnosed primary central nervous system diffuse large B-cell lymphoma
* Adequate hematologic function: ANC ≥1.0×10⁹/L, PLT ≥75×10⁹/L
* Adequate hepatic function: ALT/AST ≤3×ULN; total bilirubin ≤1.5×ULN
* Adequate renal function: serum creatinine ≤2×ULN or CrCl ≥40 mL/min
* LVEF ≥55% by echocardiography
* Baseline oxygen saturation \>92% on room air
* Expected survival ≥3 months
Exclusion Criteria:
* Prior anti-lymphoma therapy other than corticosteroids.
* Uncontrolled significant cardiovascular or cerebrovascular disease.
* Uncontrolled active systemic bacterial, fungal, or viral infection.
* Active hepatitis B and/or active hepatitis C (HCV RNA positive). Patients with positive hepatitis B surface antigen and/or core antibody but HBV-DNA \< 1000 IU/mL may be included and should receive concurrent oral antiviral prophylaxis against HBV reactivation.
* Hypersensitivity to any study drug or its components.
* Other active malignancy, except for adequately controlled non-melanoma skin cancer, in situ carcinoma, or malignancy that has been in complete remission for ≥5 years.
* Pregnant or lactating women. Fertile patients unwilling to use effective contraception.
* Other conditions deemed inappropriate by the investigator.
Primary outcome measure(s)
Overall response rate (ORR) — up to 2 years The proportion of subjects achieving either a complete response (CR) or partial response (PR) after treatment with R-PMDT, as assessed by the Lugano criteria.
Trial sites (1)
Facility
City
Region
Status
Institute of Hematology & Blood Diseases Hospital
Tianjin
China
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.